XORTX Therapeutics Inc（XRTX）股票分析

AI 分析 of XORTX Therapeutics Inc (XRTX)

卖出

XORTX Therapeutics Inc is not a good buy right now due to its significant financial losses and poor technical indicators. The stock is currently priced at $0.87, which is close to its 52-week low of $0.83, indicating weak market performance. Additionally, the RSI is at a low 24.41, suggesting the stock is oversold, but this does not guarantee a rebound. The company has reported a staggering year-to-date change of -69.47% and has a forward P/E ratio of 0.9621, indicating potential undervaluation but also reflecting ongoing financial struggles. The main risk is its negative net income, which reached -1,690,734 USD in Q2 2026, highlighting ongoing financial instability.

估值指标

XORTX Therapeutics Inc（XRTX）当前预期市盈率为 0.96，5 年平均预期市盈率为 -0.97。

预期市盈率

高估

5 年均值 P/E

-0.97

当前P/E

0.96

高估

0.17

低估

-2.11

预期 EV/EBITDA

合理

5 年均值 EV/EBITDA

0.08

当前EV/EBITDA

0.00

高估

0.32

低估

-0.17

预期市销率

合理

5 年均值 P/S

0.36

当前P/S

0.08

高估

1.34

低估

-0.61

Alphio AI 对 XRTX 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重（25 / 50 / 25），不构成保证。

乐

乐观

乐观 · 25%XRTX

$0.91

情景价格

基

基准

基准 · 50%XRTX

$0.82

情景价格

悲

悲观

悲观 · 25%XRTX

$0.78

情景价格

XRTX 常见问题 —— 由 Alphio AI 解答

XORTX Therapeutics Inc. is a pharmaceutical company. The Company is engaged in developing medications that improve the quality of life and health of individuals with gout and other important diseases. It has three clinically advanced products in development: its lead program, XRx-026 program for the treatment of gout; XRx-008 program for autosomal dominant polycystic kidney disease (ADPKD); and XRx-101 for acute kidney and other acute organ injury associated with respiratory virus infections. In addition, the Company is developing XRx-225, a pre-clinical stage program for Type II diabetic nephropathy. It is working to advance products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit the production of uric acid. The XRx-026 program is designed to decrease the chronically high serum uric acid concentration in the blood (SUA) by inhibiting the production of uric acid by the xanthine oxidase enzyme by administering a xanthine oxidase inhibitor-oxypurinol. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

XORTX Therapeutics Inc is not a good buy right now due to its significant financial losses and poor technical indicators. The stock is currently priced at $0.87, which is close to its 52-week low of $0.83, indicating weak market performance. Additionally, the RSI is at a low 24.41, suggesting the stock is oversold, but this does not guarantee a rebound. The company has reported a staggering year-to-date change of -69.47% and has a forward P/E ratio of 0.9621, indicating potential undervaluation but also reflecting ongoing financial struggles. The main risk is its negative net income, which reached -1,690,734 USD in Q2 2026, highlighting ongoing financial instability.